Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials

  1. Barbarot, S.
  2. Wollenberg, A.
  3. Silverberg, J.I.
  4. Deleuran, M.
  5. Pellacani, G.
  6. Armario-Hita, J.C.
  7. Chen, Z.
  8. Shumel, B.
  9. Eckert, L.
  10. Gadkari, A.
  11. Lu, Y.
  12. Rossi, A.B.
Aldizkaria:
Journal of Dermatological Treatment

ISSN: 1471-1753,  0954-6634

Argitalpen urtea: 2022

Alea: 33

Zenbakia: 1

Orrialdeak: 266-277

Mota: Artikulua

DOI: 10.1080/09546634.2020.1750550 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus